Agitation in the inpatient psychiatric setting: A review of clinical presentation, burden, and treatment

Journal of Psychiatric Practice

Volumn 17, Issue 3, 2011, Pages 170-185

  Hankin, Cheryl S ^a   Bronstone, Amy ^a   Koran, Lorrin M ^b  

^a BioMedEcon LLC   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

agitation; clinical presentation; inpatient; psychiatric disorder; treatment

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CLONAZEPAM; DIAZEPAM; DROPERIDOL; HALOPERIDOL; LORAZEPAM; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; TIOTIXENE; VALPROATE SEMISODIUM; ZIPRASIDONE;

ADVERSE OUTCOME; AGGRESSION; AGITATION; AKATHISIA; BEHAVIOR DISORDER; BIPOLAR DISORDER; BIPOLAR MANIA; BRADYCARDIA; CLINICAL FEATURE; DISINHIBITION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPHORIA; DYSTONIA; ECG ABNORMALITY; ECONOMIC ASPECT; EXTRAPYRAMIDAL SYMPTOM; HALF LIFE TIME; HEALTH CARE COST; HEALTH CARE SYSTEM; HOSPITAL PATIENT; HOSPITAL PERSONNEL; HOSTILITY; HUMAN; HYPOTENSION; IMPULSIVENESS; IRRITABILITY; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PSYCHIATRIC DEPARTMENT; PSYCHIATRIC TREATMENT; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SUBSTANCE ABUSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TORSADE DES POINTES; VIOLENCE; WEIGHT GAIN;

AGGRESSION; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; COMBINED MODALITY THERAPY; DANGEROUS BEHAVIOR; HOSPITALS, PSYCHIATRIC; HUMANS; INPATIENTS; MENTALLY ILL PERSONS; PSYCHOMOTOR AGITATION; RESTRAINT, PHYSICAL; RISK FACTORS; RISK MANAGEMENT; SCHIZOPHRENIA; TREATMENT OUTCOME; VIOLENCE;

EID: 79958074864     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000398410.21374.7d     Document Type: Review

References (154)

1. Powell G, Caan W, Crowe M. What events precede violent incidents in psychiatric hospitals? Br J Psychiatry 1994; 165:107-12. (Pubitemid 24224844)
2. Sheridan M, Henrion R, Robinson L, et al. Precipitants of violence in a psychiatric inpatient setting. Hosp Community Psychiatry 1990;41:776-80. (Pubitemid 20244683)
3. Whittington R, Patterson P. Verbal and non-verbal behavior immediately prior to aggression by mentally disordered people: Enhancing the assessment of risk. J Psychiatr Ment Health Nurs 1996;3:47-54. (Pubitemid 126733944)
4. Lee HK, Villar O, Juthani N, et al. Characteristics and behavior of patients involved in psychiatric ward incidents. Hosp Community Psychiatry 1989;40:1295-7. (Pubitemid 20045847)
5. Aiken GJ. Assaults on staff in a locked ward: Prediction and consequences. Med Sci Law 1984;24:199-207. (Pubitemid 14083904)
6. Crowner ML, Peric G, Stepcic F, et al. Assailant and victim behaviors immediately preceding inpatient assault. Psychiatr Q 2005;76:243-56. (Pubitemid 40922157)
7. Citrome L. Atypical antipsychotics for acute agitation. New intramuscular options offer advantages. Postgrad Med 2002;112:85-8, 94-6.
8. Owen C, Tarantello C, Jones M, et al. Repetitively violent patients in psychiatric units. Psychiatr Serv 1998;49: 1458-61. (Pubitemid 28513659)
9. Allen MH, Currier GW, Carpenter D, et al. The expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract 2005;11(Suppl 1):5-108.
10. Citrome L. New treatments for agitation. Psychiatr Q 2004;75:197-213. (Pubitemid 38881694)
11. Coburn VA, Mycyk MB. Physical and chemical restraints. Emerg Med Clin North Am 2009;27:655-67, ix.
12. Rossi J, Swan MC, Isaacs ED. The violent or agitated patient. Emerg Med Clin North Am 2010;28:235-56.
13. Zeller SL. Treatment of psychiatric patients in emergency settings. Prim Psychiatry 2010;17:35-41.
14. Cornaggia CM, Beghi M, Pavone F, et al. Aggression in psychiatry wards: A systematic review. Psychiatry Res 2011 Jan 12. [Epub ahead of print].
15. Barlow K, Grenyer B, Ilkiw-Lavalle O. Prevalence and precipitants of aggression in psychiatric inpatient units. Aust N Z J Psychiatry 2000;34:967-74.
16. Binder RL, McNiel DE. Effects of diagnosis and context on dangerousness. Am J Psychiatry 1988;145:728-32.
17. Tardiff K. Characteristics of assaultive patients in private hospitals. Am J Psychiatry 1984;141:1232-5. (Pubitemid 14011498)
18. Lion JR, Synder W, Merrill GL. Underreporting of assaults on staff in a state hospital. Hosp Community Psychiatry 1981;32:497-8. (Pubitemid 11048673)
19. McNiel DE, Binder RL, Greenfield TK. Predictors of violence in civilly committed acute psychiatric patients. Am J Psychiatry 1988;145:965-70.
20. Flannery RB, Staffieri A, Hildum S, et al. The violence triad and common single precipitants to psychiatric patient assaults on staff: 16-year analysis of the Assaulted Staff Action Program. Psychiatr Q 2010 Sep 18. [Epub ahead of print].
21. Cooper SJ, Browne FW, McClean KJ, et al. Aggressive behaviour in a psychiatric observation ward. Acta Psychiatr Scand 1983;68:386-93. (Pubitemid 14232002)
22. Quinsey VL, MacGuire A. Maximum security psychiatric patients: Actuarial and clinical prediction of dangerousness. J Interpers Violence 1986;1:143-71.
23. Ilkiw-Lavalle O, Grenyer BF. Differences between patient and staff perceptions of aggression in mental health units. Psychiatr Serv 2003;54:389-93. (Pubitemid 36753015)
24. Duxbury J, Whittington R. Causes and management of patient aggression and violence: Staff and patient perspectives. J Adv Nurs 2005;50:469-78. (Pubitemid 40745025)
25. Morrison EF. A hierarchy of aggressive and violent behaviors among psychiatric inpatients. Hosp Community Psychiatry 1992;43:505-6.
26. Owen C, Tarantello C, Jones M, et al. Violence and aggression in psychiatric units. Psychiatr Serv 1998;49:1452-7. (Pubitemid 28513658)
27. Doyle M, Dolan M, McGovern J. The validity of North American risk assessment tools in predicting inpatient violent behaviour in England. Legal and Criminological Psychology 2002;7:141-54.
28. Haim R, Rabinowitz J, Lereya J, et al. Predictions made by psychiatrists and psychiatric nurses of violence by patients. Psychiatr Serv 2002;53:622-4. (Pubitemid 34454185)
29. National Institute for Health and Clinical Excellence. Violence: The short-term management of disturbed/violent behaviour in in-patient psychiatric settings and emergency departments. London: Royal College of Nursing; 2006.
30. Daffern M. The predictive validity and practical utility of structured schemes used to assess risk for aggression in psychiatric inpatient settings. Aggress Violent Behav 2007;12:116-30. (Pubitemid 46001608)
31. Ogloff JR, Daffern M. The dynamic appraisal of situational aggression: An instrument to assess risk for imminent aggression in psychiatric inpatients. Behav Sci Law 2006;24:799-813. (Pubitemid 46174444)
32. McNiel DE, Gregory AL, Lam JN, et al. Utility of decision support tools for assessing acute risk of violence. J Consult Clin Psychol 2003;71:945-53. (Pubitemid 37151557)
33. Berg AZ, Bell CC, Tupin J. Clinician safety: Assessing and managing the violent patient. New Dir Ment Health Serv 2000 Summer;(86):9-29.
34. Daffern M, Howells K, Ogloff J. What's the point? Towards a methodology for assessing the function of psychiatric inpatient aggression. Behav Res Ther 2007;45:101-11. (Pubitemid 44648000)
35. Almvik R, Woods P, Rasmussen K. The Broset violence checklist: Sensitivity, specificity, and interrater reliability. J Interpers Violence 2000;15:1284-96.
36. Clarke DE, Brown AM, Griffith P. The Broset Violence Checklist: Clinical utility in a secure psychiatric intensive care setting. J Psychiatr Ment Health Nurs 2010;17: 614-20.
37. Abderhalden C, Needham I, Miserez B, et al. Predicting inpatient violence in acute psychiatric wards using the Broset-Violence-Checklist: A multicentre prospective cohort study. J Psychiatr Ment Health Nurs 2004;11: 422-7. (Pubitemid 39091507)
38. Lanza ML. Nurses as patient assault victims: An update, synthesis, and recommendations. Arch Psychiatr Nurs 1992;6:163-71.
39. Nolan KA, Citrome L. Reducing inpatient aggression: Does paying attention pay off? Psychiatr Q 2008;79:91-5. (Pubitemid 351748182)
40. Munro V. Why do nurses neglect to report violent incidents? Nurs Times 2002;98:38-9.
41. Nijman HL, Palmstierna T, Almvik R, et al. Fifteen years of research with the Staff Observation Aggression Scale: A review. Acta Psychiatr Scand 2005;111:12-21.
42. Rodriguez-Acosta RL, Myers DJ, Richardson DB, et al. Physical assault among nursing staff employed in acute care. Work 2010;35:191-200.
43. Nijman H, Bowers L, Oud N, et al. Psychiatric nurses' experiences with inpatient aggression. Aggress Behav 2005;31:217-27. (Pubitemid 40580036)
44. Foster C, Bowers L, Nijman H. Aggressive behaviour on acute psychiatric wards: Prevalence, severity and management. J Adv Nurs 2007;58:140-9.
45. Black KJ, Compton WM, Wetzel M, et al. Assaults by patients on psychiatric residents at three training sites. Hosp Community Psychiatry 1994;45:706-10. (Pubitemid 24208999)
46. Schwartz TL, Park TL. Assaults by patients on psychiatric residents: A survey and training recommendations. Psychiatr Serv 1999;50:381-3. (Pubitemid 29122568)
47. Chaimowitz GA, Moscovitch A. Patient assaults on psychiatric residents: The Canadian experience. Can J Psychiatry 1991;36:107-11.
48. Gray GE. Assaults by patients against psychiatric residents at a public psychiatric hospital. Acad Psychiatry 1989;13:81-6.
49. Ruben I, Wolkon G, Yamamoto J. Physical attacks on psychiatric residents by patients. J Nerv Ment Dis 1980;168: 243-5. (Pubitemid 10150679)
50. Sansone RA, Taylor SB, Gaither GA. Patient assaults on psychiatry residents: Results of a national survey. Traumology 2002;8:211-4.
51. Madden DJ, Lion JR, Penna MW. Assaults on psychiatrists by patients. Am J Psychiatry 1976;133:422-5.
52. Hatti S, Dubin WR, Weiss KJ. A study of the circumstances surrounding patient assaults on psychiatrists. Hosp Community Psychiatry 1982;33:660-1. (Pubitemid 12064426)
53. Whitman RM, Armao BB, Dent OB. Assault on the therapist. Am J Psychiatry 1976;133:426-9.
54. Frueh BC, Knapp RG, Cusack KJ, et al. Patients' reports of traumatic or harmful experiences within the psychiatric setting. Psychiatr Serv 2005;56:1123-33. (Pubitemid 41266842)
55. Lanza ML. The reactions of nursing staff to physical assault by a patient. Hosp Community Psychiatry 1983; 34:44-7. (Pubitemid 13108263)
56. Nolan KA, Shope CB, Citrome L, et al. Staff and patient views of the reasons for aggressive incidents: A prospective, incident-based study. Psychiatr Q 2009;80:167-72.
57. Ketelsen R, Zechert C, Driessen M, et al. Characteristics of aggression in a German psychiatric hospital and predictors of patients at risk. J Psychiatr Ment Health Nurs 2007;14:92-9.
58. Pearson M, Wilmot E, Padi M. A study of violent behaviour among in-patients in a psychiatric hospital. Br J Psychiatry 1986;149:232-5. (Pubitemid 16076259)
59. Caldwell MF. Incidence of PTSD among staff victims of patient violence. Hosp Community Psychiatry 1992;43: 838-9.
60. Richter D, Berger K. Post-traumatic stress disorder following patient assaults among staff members of mental health hospitals: A prospective longitudinal study. BMC Psychiatry 2006;6:15.
61. Needham I, Abderhalden C, Halfens RJ, et al. Non-somatic effects of patient aggression on nurses: A systematic review. J Adv Nurs 2005;49:283-96. (Pubitemid 40221692)
62. Gerberich SG, Church TR, McGovern PM, et al. An epidemiological study of the magnitude and consequences of work related violence: The Minnesota Nurses' Study. Occup Environ Med 2004;61:495-503. (Pubitemid 38725619)
63. Ryan EP, Aaron J, Burnette ML, et al. Emotional responses of staff to assault in a pediatric state hospital. J Am Acad Psychiatry Law 2008;36:360-8.
64. Cheung P, Schweitzer I, Tuckwell V, et al. A prospective study of assaults on staff by psychiatric in-patients. Med Sci Law 1997;37:46-52. (Pubitemid 127459960)
65. Wildgoose J, Briscoe M, Lloyd K. Psychological and emotional problems in staff following assaults by patients. Psychiatr Bull R Coll Psychiatr 2003;27:295-7. (Pubitemid 36980669)
66. Cusack KJ, Frueh BC, Hiers T, et al. Trauma within the psychiatric setting: A preliminary empirical report. Adm Policy Ment Health 2003;30:453-60. (Pubitemid 36999188)
67. Source for historical conversion values: www.oanda.com /currency/historical-rates (annual average conversion rates were used). The medical component of the Consumer Price Index was used to update to 2010 USD. To access this table, go to www.bls.gov/cpi/data.htm and select the database for All Urban Consumers and then check the box for CPI Medical Care. The CPI for medical care for 2010 is 388.436. Thus, in converting $38,000 1987 USD, one uses the medical component CPI for 1987, which is 130.1: $38,000 * 388.436)/130.1 = $113,456 2010 USD. The medical component CPI for 1988 is 138.6. and for 2005 is 323.2.
68. Lanza ML, Milner J. The dollar cost of patient assault. Hosp Community Psychiatry 1989;40:1227-9.
69. Hunter M, Carmel H. The cost of staff injuries from inpatient violence. Hosp Community Psychiatry 1992;43: 586-8.
70. Hillbrand M, Foster HG, Spitz RT. Characteristics and cost of staff injuries in a forensic hospital. Psychiatr Serv 1996;47:1123-5. (Pubitemid 26327897)
71. Sullivan C, Yuan C. Workplace assaults on minority health and mental health care workers in Los Angeles. Am J Public Health 1995;85:1011-4.
72. Comptroller and Auditor General. A safer place to work: Protecting NHS hospital and ambulance staff from violence and aggression. Report by the Comptroller and Auditor General HC 527 Session 2002-2003: 27 March 2003. London: House of Commons; 2003.
73. Wales Audit Office. Protecting the NHS Trust staff from violence and aggression. September 2005 (Available at www.wales.nhs.uk/documents/NHS- Violence-and-agression. pdf, accessed March 22, 2011).
74. Bowers L, Whittington R, Nolan P, et al. The City 128 Study of Observation and Outcomes on Acute Psychiatric Wards. Research report prepared for the National Co-ordinating Centre for the National Institute for Health Research Service Delivery and Organisation Programme (NCCSDO). London: Queen's Printer and Controller of HMSO; December 2006.
75. Flood C, Bowers L, Parkin D. Estimating the costs of conflict and containment on adult acute inpatient psychiatric wards. Nurs Econ 2008;26:325-30, 4.
76. Jaffe A, Levine J, Citrome L. "Stat" medication administration predicts hospital discharge. Psychiatr Q 2009;80: 65-73.
77. Distasio CA. Violence in health care: Institutional strategies to cope with the phenomenon. Health Care Superv 1994;12:1-34.
78. Cowin L, Davies R, Estall G, et al. De-escalating aggression and violence in the mental health setting. Int J Ment Health Nurs 2003;12:64-73.
79. Novitsky MA, Julius RJ, Dubin WR. Non-pharmacologic management of violence in psychiatric emergencies. Prim Psychiatry 2009;19:49-53.
80. Ativan tablets [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals; April 2007.
81. Ativan injection [package insert]. Deerfield, IL: Baxter Healthcare Corporation; November 2006.
82. Allen MH. Managing the agitated psychotic patient: A reappraisal of the evidence. J Clin Psychiatry 2000;61 Suppl 14:11-20. (Pubitemid 32064772)
83. Haldol [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceuticals; June 2009.
84. Miller DD. Atypical antipsychotics: Sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry 2004;6:3-7.
85. Battaglia J. Pharmacological management of acute agitation. Drugs 2005;65:1207-22. (Pubitemid 41032047)
86. Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry 1999;60(Suppl 10):20-30. (Pubitemid 29237172)
87. Loxitane IM prescribing information, 2009 (available at http://www.rxlist.com/loxitane-drug.htm, accessed March 22, 2011).
88. Abilify [package insert]. Tokyo, Japan: Otsuka Pharmaceutical Company; 2009.
89. Tran-Johnson TK, Sack DA, Marcus RN, et al. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007;68:111-9. (Pubitemid 46220132)
90. Andrezina R, Josiassen RC, Marcus RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: A double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl) 2006;188:281-92. (Pubitemid 44387456)
91. Zyprexa [package insert]. Indianapolis, IN: Eli Lilly and Company; August 2009.
92. Wright P, Birkett M, David SR, et al. Double-blind, placebo- controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001;158:1149-51. (Pubitemid 32623122)
93. Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002;59: 441-8. (Pubitemid 34477680)
94. Seroquel [package insert]. Wilmington, DE: AstraZeneca; July 2009.
95. Currier GW, Trenton AJ, Walsh PG, et al. A pilot, openlabel safety study of quetiapine for treatment of moderate psychotic agitation in the emergency setting. J Psychiatr Pract 2006;12:223-8. (Pubitemid 44180545)
96. Risperdal [package insert]. Titusville, NJ: Janssen; July 2009.
97. Currier GW, Medori R. Orally versus intramuscularly administered antipsychotic drugs in psychiatric emergencies. J Psychiatr Pract 2006;12:30-40. (Pubitemid 44378045)
98. Geodon [package insert]. New York, NY: Pfizer; June 2008.
99. Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: A double-blind, randomized trial. Psychopharmacology (Berl) 2001;155:128-34. (Pubitemid 32417820)
100. Lesem MD, Zajecka JM, Swift RH, et al. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001;62:12-8. (Pubitemid 32154312)
101. Preval H, Klotz SG, Southard R, et al. Rapid-acting IM ziprasidone in a psychiatric emergency service: A naturalistic study. Gen Hosp Psychiatry 2005;27:140-4. (Pubitemid 40348779)
102. Satterthwaite TD, Wolf DH, Rosenheck RA, et al. A metaanalysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry 2008;69:1869-79.
103. Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: A quantitative review of efficacy and safety. J Clin Psychiatry 2007;68: 1876-85.
104. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004;24:62-9. (Pubitemid 38134167)
105. King DJ, Burke M, Lucas RA. Antipsychotic drug-induced dysphoria. Br J Psychiatry 1995;167:480-2. (Pubitemid 26194149)
106. Seitz DP, Gill SS. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: Case reports and a review of the literature. Psychosomatics 2009;50:8-15.
107. Goodnick PJ, Rodriguez L, Santana O. Antipsychotics: Impact on prolactin levels. Expert Opin Pharmacother 2002;3:1381-91.
108. Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997;15:335-40. (Pubitemid 27284198)
109. Glazer WM. Does loxapine have "atypical" properties? Clinical evidence. J Clin Psychiatry 1999;60(Suppl 10):42-6. (Pubitemid 29237174)
110. Chakrabarti A, Bagnall A, Chue P, et al. Loxapine for schizophrenia. Cochrane Database Syst Rev 2007: CD001943.
111. Bednar MM, Harrigan EP, Anziano RJ, et al. The QT interval. Prog Cardiovasc Dis 2001;43:1-45. (Pubitemid 32223496)
112. Greenblatt DJ, Shader RI, Franke K, et al. Pharmaco - kinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. J Pharm Sci 1979;68: 57-63. (Pubitemid 9061001)
113. Greenblatt DJ, Divoll M, Harmatz JS, et al. Pharmaco - kinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. J Pharm Sci 1982;71:248-52. (Pubitemid 12112857)
114. Allen MH, Carpenter D, Sheets JL, et al. What do consumers say they want and need during a psychiatric emergency? J Psychiatr Pract 2003;9:39-58. (Pubitemid 36717621)
115. Mohr P, Pecenak J, Svestka J, et al. Treatment of acute agitation in psychotic disorders. Neuro Endocrinol Lett 2005;26:327-35. (Pubitemid 41518772)
116. Gao K, Kemp DE, Ganocy SJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: A systematic review. J Clin Psychopharmacol 2008;28:203-9. (Pubitemid 351417126)
117. Lim HK, Kim JJ, Pae CU, et al. Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: A randomized open, prospective study. Neuropsychobiology 2010;62: 81-6.
118. Currier GW, Chou JC, Feifel D, et al. Acute treatment of psychotic agitation: A randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry 2004;65:386-94.
119. Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group. J Clin Psychiatry 2000;61:933-41. (Pubitemid 32058009)
120. Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001;21:389-97. (Pubitemid 32673028)
121. Weiden PJ. EPS profiles: The atypical antipsychotics are not all the same. J Psychiatr Pract 2007;13:13-24. (Pubitemid 46148428)
122. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics : Differential risk and clinical implications. CNS Drugs 2007;21:911-36. (Pubitemid 47557106)
123. Zacher JL, Roche-Desilets J. Hypotension secondary to the combination of intramuscular olanzapine and intramuscular lorazepam. J Clin Psychiatry 2005;66:1614-5. (Pubitemid 43068709)
124. Marder SR, Sorsaburu S, Dunayevich E, et al. Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation. J Clin Psychiatry 2010;71:433-41.
125. Naso AR. Optimizing patient safety by preventing combined use of intramuscular olanzapine and parenteral benzodiazepines. Am J Health Syst Pharm 2008;65: 1180-3. (Pubitemid 351874863)
126. Strom BL, Eng SM, Faich G, et al. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry 2011;168:193-201.
127. Citrome L. Aerosolised antipsychotic assuages agitation: Inhaled loxapine for agitation associated with schizophrenia or bipolar disorder. Int J Clin Pract 2011;65:330-40.
128. Kay SR, Fiszbein A, Opler LA.. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76. (Pubitemid 18039085)
129. Lesem MD, Tran-Johnson TK, Riesenberg RA, et al. Rapid acute treatment of agitation in individuals with schizophrenia: Multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry 2011;198:51-8.
130. Allen MH, Feifel D, Lesem MD, et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011 Jan 25. [Epub ahead of print].
131. Nordstrom K. Inhaled loxapine for acute agitation in schizophrenia and bipolar disorder. Future Neurol 2009;4: 539-45.
132. Alexza Pharmaceuticals completes end-of-review meeting with FDA for AZ-004 (Staccato(R) Loxapine) NDA. 2011. (Available at nocache-phx.corporate-ir. net/phoenix.zhtml?c=196151&p=RssLanding&cat=news&id=1516596, accessed March 22, 2011).
133. Fisher WA. Restraint and seclusion: A review of the literature. Am J Psychiatry 1994;151:1584-91. (Pubitemid 24337588)
134. Nelstrop L, Chandler-Oatts J, Bingley W, et al. A systematic review of the safety and effectiveness of restraint and seclusion as interventions for the short-term management of violence in adult psychiatric inpatient settings and emergency departments. Worldviews Evid Based Nurs 2006;3:8-18. (Pubitemid 43356999)
135. Medicare and Medicaid Programs; Hospital Conditions of Participation: Patients' Rights; Final Rule. Federal Register 71(8 December 2006):71378-428.
136. Borckardt JJ, Grubaugh AL, Pelic CG, et al. Enhancing patient safety in psychiatric settings. J Psychiatr Pract 2007;13:355-61. (Pubitemid 350158941)
137. Brown JS, Tooke SK. On the seclusion of psychiatric patients. Soc Sci Med 1992;35:711-21.
138. Ramchandani D, Akhtar S, Helfrich J. Seclusion of psychiatric inpatients: A general hospital perspective. Int J Soc Psychiatry 1981;27:225-31. (Pubitemid 11058422)
139. Schwab PJ, Lahmeyer CB. The uses of seclusion on a general hospital psychiatric unit. J Clin Psychiatry 1979;40: 228-31. (Pubitemid 9191955)
140. Plutchik R, Karasu TB, Conte HR, et al. Toward a rationale for the seclusion process. J Nerv Ment Dis 1978;166: 571-9. (Pubitemid 8398570)
141. Oldham JM, Russakoff LM, Prusnofsky L. Seclusion. patterns and milieu. J Nerv Ment Dis 1983;171:645-50.
142. Mattson MR, Sacks MH. Seclusion: Uses and complications. Am J Psychiatry 1978;135:1210-3. (Pubitemid 9033785)
143. Convertino K, Pinto RP, Fiester AR. Use of inpatient seclusion at a community mental health center. Hosp Community Psychiatry 1980;31:848-50. (Pubitemid 11170954)
144. Keski-Valkama A, Sailas E, Eronen M, et al. The reasons for using restraint and seclusion in psychiatric inpatient care: A nationwide 15-year study. Nord J Psychiatry 2010;64:136-44.
145. Wynn R. Psychiatric inpatients' experiences with restraint. J Forens Psychiatry Psychol 2004;15.
146. Fish R, Culshaw E. The last resort? Staff and client perspectives on physical intervention. J Intellect Disabil 2005;9:93-107. (Pubitemid 40895250)
147. Chien WT, Chan CW, Lam LW, et al. Psychiatric inpatients' perceptions of positive and negative aspects of physical restraint. Patient Educ Couns 2005;59:80-6. (Pubitemid 41399881)
148. Bonner G, Lowe T, Rawcliffe D, et al. Trauma for all: A pilot study of the subjective experience of physical restraint for mental health inpatients and staff in the UK. J Psychiatr Ment Health Nurs 2002;9:465-73.
149. Binder RL, McCoy SM. A study of patients' attitudes toward placement in seclusion. Hosp Community Psychiatry 1983;34:1052-4. (Pubitemid 14243339)
150. Robins CS, Sauvageot JA, Cusack KJ, et al. Consumers' perceptions of negative experiences and "sanctuary harm" in psychiatric settings. Psychiatr Serv 2005;56:1134-8. (Pubitemid 41266843)
151. Lee S, Gray R, Gournay K, et al. Views of nursing staff on the use of physical restraint. J Psychiatr Ment Health Nurs 2003;10:425-30. (Pubitemid 37249106)
152. Sequeira H, Halstead S. Psychological effects on nursing staff of administering physical restraint in a secure psychiatric hospital: 'When I go home, it's then that I think about it'. The British Journal of Forensic Practice 2004;6:3-15. (Pubitemid 38430778)
153. Carmel H, Hunter M. Staff injuries from inpatient violence. Hosp Community Psychiatry 1989;40:41-6. (Pubitemid 19029897)
154. Jarrett M, Bowers L, Simpson A. Coerced medication in psychiatric inpatient care: Literature review. J Adv Nurs 2008;64:538-48.